title: Regulation of membrane cholecystokinin-2 receptor by agonists enables classification of partial agonists as biased agonists.
abstract: Given the importance of G-protein-coupled receptors as pharmacological targets in medicine, efforts directed at understanding the molecular mechanism by which pharmacological compounds regulate their presence at the cell surface is of paramount importance. In this context, using confocal microscopy and bioluminescence resonance energy transfer, we have investigated internalization and intracellular trafficking of the cholecystokinin-2 receptor (CCK2R) in response to both natural and synthetic ligands with different pharmacological features. We found that CCK and gastrin, which are full agonists on CCK2R-induced inositol phosphate production, rapidly and abundantly stimulate internalization. Internalized CCK2R did not rapidly recycle to plasma membrane but instead was directed to late endosomes/lysosomes. CCK2R endocytosis involves clathrin-coated pits and dynamin and high affinity and prolonged binding of β-arrestin1 or -2. Partial agonists and antagonists on CCK2R-induced inositol phosphate formation and ERK1/2 phosphorylation did not stimulate CCK2R internalization or β-arrestin recruitment to the CCK2R but blocked full agonist-induced internalization and β-arrestin recruitment. The extreme C-terminal region of the CCK2R (and more precisely phosphorylatable residues Ser(437)-Xaa(438)-Thr(439)-Thr(440)-Xaa(441)-Ser(442)-Thr(443)) were critical for β-arrestin recruitment. However, this region and β-arrestins were dispensable for CCK2R internalization. In conclusion, this study allowed us to classify the human CCK2R as a member of class B G-protein-coupled receptors with regard to its endocytosis features and identified biased agonists of the CCK2R. These new important insights will allow us to investigate the role of internalized CCK2R·β-arrestin complexes in cancers expressing this receptor and to develop new diagnosis and therapeutic strategies targeting this receptor.
authors.affiliation: INSERM, Unit 858, 12 MR, 1 Avenue Jean Poulhés, 31432 Toulouse Cedex 4, France.
authors.forename: Rémi
authors.initials: R
authors.lastname: Magnan
authors.forename: Bernard
authors.initials: B
authors.lastname: Masri
authors.forename: Chantal
authors.initials: C
authors.lastname: Escrieut
authors.forename: Magali
authors.initials: M
authors.lastname: Foucaud
authors.forename: Pierre
authors.initials: P
authors.lastname: Cordelier
authors.forename: Daniel
authors.initials: D
authors.lastname: Fourmy
mesh_terms: D019390:Arrestins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D002766:Cholecystokinin / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology; D011992:Endosomes / Q000235:genetics / Q000378:metabolism; D005755:Gastrins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D057809:HEK293 Cells; D006801:Humans; D008247:Lysosomes / Q000235:genetics / Q000378:metabolism; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects / Q000502:physiology; D043887:Receptor, Cholecystokinin B / Q000819:agonists* / Q000235:genetics / Q000378:metabolism*; D000071557:beta-Arrestins
chemical_list: D019390:Arrestins; D005755:Gastrins; D043887:Receptor, Cholecystokinin B; D000071557:beta-Arrestins; D002766:Cholecystokinin; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3